Skip to main content

Enliven Therapeutics, Inc.

ELVN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001672619

In the last 90 days, Enliven Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 214 institutions reported holding it in 13F filings for Q2 2026, worth $4.06B in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Enliven Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
8 filings
4 insiders, $11.8M in total
Insiders trading
4
Net value
−$11.8M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Enliven Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Enliven Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Hohl BenjaminCHIEF FINANCIAL OFFICER38,000Sep 21, 20268
Collins Helen LouiseCHIEF MEDICAL OFFICER25,000Sep 21, 202611
Derynck Mika KDirector0Aug 6, 20262
Kunkel Lori AnneDirector41,884Jul 8, 20264
OrbiMed Advisors LLC10% Owner6,555,102IndirectJun 24, 20262
OrbiMed Capital GP VII LLC10% Owner6,555,102IndirectJun 24, 20262
OrbiMed Genesis GP LLC10% Owner6,555,102IndirectJun 24, 20262
Heyman Richard A.Director22,647IndirectFeb 19, 20264
Garland J. ScottDirector–Feb 17, 20262
Gupta RishiDirector7,663,349IndirectFeb 17, 20261
Bauer JakeDirector87,372Feb 17, 20261
Ballal Rahul D.Director22,341Feb 17, 20261
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER18,750Feb 17, 20267
Patel AnishCHIEF OPERATING OFFICER20,000Feb 17, 20265
Fair Richard A.PRESIDENT AND CEO–Dec 12, 20251
Kintz SamuelPRESIDENT AND CEO890,392IndirectNov 19, 20252
Phillips Andrew JohnDirector–Feb 10, 20250
Schwab Andrew J.10% Owner635,341IndirectFeb 16, 20240
Parmar Kush10% Owner635,341IndirectFeb 16, 20240
5AM Opportunities I, L.P.10% Owner635,341IndirectFeb 16, 20240
5AM Ventures VI, L.P.10% Owner635,341IndirectFeb 16, 20240
5AM Opportunities I (GP), LLC10% Owner635,341IndirectFeb 16, 20240
5AM Partners VI, LLC10% Owner635,341IndirectFeb 16, 20240
RA Capital Healthcare Fund LPOther: Former 10% owner2,122,465IndirectFeb 27, 20230
Ra Capital Management, L.P.Other: Former 10% owner2,122,465IndirectFeb 27, 20230
Kolchinsky PeterOther: Former 10% owner2,122,465IndirectFeb 27, 20230
Shah Rajeev M.Other: Former 10% owner2,122,465IndirectFeb 27, 20230
Commodore Capital LP10% Owner1,448,640IndirectFeb 27, 20230
Gray MichaelCFO & COO27,610Feb 22, 20230
Leonard Braden Michael10% Owner1,767,774IndirectJan 5, 20230
Goldfischer CarlDirector–Jun 3, 20220
Mott David MDirector229,224Jun 3, 20220
Bonita David PDirector, 10% Owner4,199,068IndirectJun 3, 20220
Dalton BarbaraDirector–Jun 3, 20220
Conner Edward R.Director–Jun 3, 20220
Chin MarkDirector2,344,072IndirectJun 3, 20220
Williams Laura ADirector–Jun 3, 20220
Kerins Patrick J10% Owner2,611,050Apr 7, 20220
Sandell Scott D10% Owner2,611,050Apr 7, 20220
Baskett Forest10% Owner2,611,050Apr 7, 20220
New Enterprise Associates 14, L.P.10% Owner2,611,050Apr 7, 20220
NEA Partners 14, L.P.10% Owner2,611,050Apr 7, 20220
Nea 14 GP, Ltd10% Owner2,611,050Apr 7, 20220
Sonsini Peter W.10% Owner2,611,050Apr 7, 20220
Florence Anthony A. Jr.10% Owner2,611,050Apr 7, 20220
Attie KennethSVP, CMO34,100Feb 1, 20220
OrbiMed Capital LLCDirector, 10% Owner1,666,666IndirectJul 16, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Apr 3, 2024 (view filing)Apr 12 daysLyssikatos Joseph PCHIEF SCIENTIFIC OFFICERSSale−12.0K$18.59−$223.1K−100.0%0 after3 lots10b5-1
Mar 29, 2024 (view filing)Mar 272 daysHohl BenjaminCHIEF FINANCIAL OFFICERSSale−3.25K$18.25−$59.3K−100.0%0 after2 lots10b5-1
Mar 27, 2024 (view filing)Mar 252 daysKintz SamuelPRESIDENT AND CEOSSale−12.0K$17.56−$210.7K−100.0%0 after2 lots10b5-1
Mar 22, 2024 (view filing)Mar 202 daysBallal Rahul D.DirectorSSale−13.3K$19.16−$254.4K−37.3%22.3K after10b5-1
Mar 21, 2024 (view filing)Mar 192 daysHeyman Richard A.DirectorSSale−1.27K$14.50−$18.4K−0.9%143.5K after10b5-1
Mar 8, 2024 (view filing)Mar 62 daysPatel AnishCHIEF OPERATING OFFICERSSale−4.88K$15.64−$76.2K−39.5%7.47K after10b5-1
Mar 4, 2024 (view filing)Feb 294 daysLyssikatos Joseph PCHIEF SCIENTIFIC OFFICERSSale−12.0K$16.42−$197.0K−100.0%0 after2 lots10b5-1
Feb 29, 2024 (view filing)Feb 272 daysHohl BenjaminCHIEF FINANCIAL OFFICERSSale−3.25K$16.97−$55.2K−100.0%0 after10b5-1
Feb 28, 2024 (view filing)Feb 262 daysKintz SamuelPRESIDENT AND CEOSSale−12.0K$16.89−$202.7K−100.0%0 after2 lots10b5-1
Feb 20, 2024 (view filing)Feb 155 daysHeyman Richard A.DirectorSSale−1.27K$17.42−$22.1K−0.9%144.7K after10b5-1
Feb 16, 2024 (view filing)4:15 PM ETFeb 142 daysSchwab Andrew J. and 5 others10% OwnerSSale−825.0K$14.90−$12.3M−56.5%635.3K after2 lots
Feb 8, 2024 (view filing)Feb 62 daysPatel AnishCHIEF OPERATING OFFICERSSale−4.88K$15.11−$73.7K−28.3%12.3K after10b5-1
Feb 2, 2024 (view filing)4:29 PM ETJan 312 daysSchwab Andrew J. and 5 others10% OwnerSSale−500.0K$15.00−$7.50M−39.3%772.0K after2 lots
Feb 1, 2024 (view filing)Jan 302 daysHeyman Richard A.DirectorSSale−1.27K$16.41−$20.8K−0.9%146.0K after10b5-1
Jan 31, 2024 (view filing)Jan 292 daysLyssikatos Joseph PCHIEF SCIENTIFIC OFFICERSSale−12.0K$15.85−$190.2K−100.0%0 after10b5-1
Jan 31, 2024 (view filing)Jan 292 daysHohl BenjaminCHIEF FINANCIAL OFFICERSSale−3.25K$15.81−$51.4K−100.0%0 after10b5-1
Jan 29, 2024 (view filing)Jan 254 daysKintz SamuelPresident and CEOSSale−12.0K$15.69−$188.3K−100.0%0 after2 lots10b5-1
Jan 24, 2024 (view filing)Jan 222 daysPatel AnishChief Operating OfficerSSale−4.88K$15.14−$73.8K−22.1%17.2K after10b5-1
Jan 3, 2024 (view filing)Dec 29, 20235 daysLyssikatos Joseph PChief Scientific OfficerSSale−12.0K$14.28−$171.4K−100.0%0 after2 lots10b5-1
Jan 2, 2024 (view filing)Dec 28, 2023-Jan 2, 20245 daysPatel AnishChief Operating OfficerSSale−13.5K$15.01−$203.3K−38.0%22.1K after3 lots10b5-1
Jan 2, 2024 (view filing)Dec 28, 2023-Jan 2, 20245 daysHohl BenjaminChief Financial OfficerSSale−11.9K$15.02−$178.3K−100.0%0 after3 lots10b5-1
Dec 28, 2023 (view filing)Dec 262 daysKintz SamuelPresident and CEOSSale−12.0K$14.64−$175.7K−100.0%0 after10b5-1
Dec 27, 2023 (view filing)Dec 22-265 daysPatel AnishChief Operating OfficerSSale−1.08K$15.03−$16.3K−3.0%35.6K after2 lots10b5-1
Dec 27, 2023 (view filing)Dec 22-265 daysHohl BenjaminChief Financial OfficerSSale−1.13K$15.06−$17.0K−100.0%0 after2 lots10b5-1
Dec 26, 2023 (view filing)Dec 21-225 daysLyssikatos Joseph PChief Scientific OfficerSSale−6.57K$13.07−$85.8K−100.0%0 after2 lots10b5-1
Dec 26, 2023 (view filing)Dec 21-225 daysKintz SamuelPresident and CEOSSale−8.20K$13.05−$106.9K−100.0%0 after2 lots
Dec 26, 2023 (view filing)Dec 21-225 daysHeyman Richard A.DirectorSSale−175$13.00−$2.27K−0.1%147.3K after2 lots10b5-1
Dec 26, 2023 (view filing)Dec 21-225 daysHeyman Richard A.DirectorSSale−41$13.00−$533−0.1%29.2K after2 lots10b5-1
Dec 21, 2023 (view filing)Dec 201 dayKintz SamuelPresident and CEOSSale−7.78K$13.01−$101.2K−100.0%0 after10b5-1
Dec 21, 2023 (view filing)Dec 19-202 daysLyssikatos Joseph PChief Scientific OfficerSSale−8.89K$13.01−$115.6K−100.0%0 after2 lots10b5-1
Dec 21, 2023 (view filing)Dec 19-202 daysHeyman Richard A.DirectorSSale−2.37K$13.02−$30.8K−1.6%147.5K after2 lots10b5-1
Dec 21, 2023 (view filing)Dec 201 dayHeyman Richard A.DirectorSSale−1.92K$13.02−$24.9K−6.1%29.3K after10b5-1
Nov 6, 2023 (view filing)Nov 33 daysLyssikatos Joseph PChief Scientific OfficerSSale−8.55K$13.08−$111.8K−100.0%0 after10b5-1
Nov 6, 2023 (view filing)Nov 33 daysKintz SamuelPresident and CEOSSale−8.03K$13.08−$105.0K−100.0%0 after10b5-1
Oct 3, 2023 (view filing)Sep 294 daysLyssikatos Joseph PChief Scientific OfficerSSale−12.0K$13.62−$163.4K−100.0%0 after10b5-1
Sep 28, 2023 (view filing)4:27 PM ETSep 262 daysSchwab Andrew J. and 5 others10% OwnerSSale−197.5K$15.00−$2.96M−18.8%854.8K after2 lots
Sep 26, 2023 (view filing)Sep 251 dayKintz SamuelPresident and CEOSSale−12.0K$13.81−$165.7K−100.0%0 after10b5-1
Aug 28, 2023 (view filing)4:20 PM ETAug 244 daysSchwab Andrew J. and 5 others10% OwnerSSale−440.0K$16.00−$7.04M−33.1%887.5K after2 lots
Feb 27, 2023 (view filing)Feb 234 daysCommodore Capital LP10% OwnerPPurchaseCommon stock, par value $0.001 per share+621.75$22.07+$13.7K+0.1%718.7K after
Feb 23, 2023 (view filing)Feb 21-222 daysCommodore Capital LP10% OwnerPPurchaseCommon stock, par value $0.001 per share+31.8K$5.15+$163.4K+1.1%2.87M after2 lots
Feb 22, 2023 (view filing)Feb 22Same dayGray MichaelCFO & COOSSale−9.86K$4.67−$46.0K−26.3%27.6K after
Feb 22, 2023 (view filing)Feb 22Same dayBallal Rahul D.Chief Executive OfficerSSale−32.9K$4.66−$153.1K−27.2%87.8K after
Feb 1, 2023 (view filing)Jan 302 daysGray MichaelCFO & COOSSale−3.60K$3.92−$14.1K−8.8%37.5K after
Feb 1, 2023 (view filing)Jan 302 daysBallal Rahul D.Chief Executive OfficerSSale−11.3K$3.91−$44.2K−8.6%120.7K after
Jan 5, 2023 (view filing)4:43 PM ETJan 32 daysRA Capital Healthcare Fund LP and 3 others10% OwnerPPurchase+629.3K$4.00+$2.52M+19.4%3.88M after
Jan 5, 2023 (view filing)Jan 32 daysLeonard Braden Michael10% OwnerSSale−1.25M$4.00−$5.00M−41.4%1.77M afterAmended
Dec 30, 2022 (view filing)Dec 30Same dayLeonard Braden Michael10% OwnerSSale−20.0K$4.04−$80.8K−8.0%230.0K after
Dec 29, 2022 (view filing)Dec 28-291 dayLeonard Braden Michael10% OwnerSSale−20.0K$4.04−$80.8K−7.4%250.0K after2 lots
Dec 27, 2022 (view filing)Dec 22-235 daysLeonard Braden Michael10% OwnerSSale−50.0K$4.06−$203.0K−15.6%270.0K after2 lots
Dec 12, 2022 (view filing)4:30 PM ETDec 8-94 daysRA Capital Healthcare Fund LP and 3 others10% OwnerPPurchase+29.9K$3.87+$115.6K+0.9%3.25M after2 lots